Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 39, Issue 3, 1997, Pages 254-258

  Newman, Edward M ^a   Carroll, Mary ^a   Akman, Steven A ^a   Chow, Warren ^a   Coluzzi, Paul ^a   Hamasaki, Victor ^a   Leong, Lucille A ^a   Margolin, Kim A ^a   Morgan, Robert J ^a   Raschko, James W ^a   Shibata, Stephen ^a   Somlo, George ^a   Tetef, Merry ^a   Yen, Yun ^a   Ahn, Chul W ^a   Doroshow, James H ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Drug therapy; Human; Hydroxyurea; Pharmacokinetics; Toxicity

Indexed keywords

DEXAMETHASONE; DIPHENHYDRAMINE; HYDROXYUREA;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORIMETRY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; SOLID TUMOR; STEADY STATE; THROMBOCYTOPENIA;

EID: 10544252684     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050569     Document Type: Article

References (20)

1. Belt RJ, Haas CD, Kennedy J, Taylor S (1980) Studies of hydroxyurea administered by continuous infusion. Cancer 46: 455
2. Biron F, Lucht F, Peyramond D, Fresard A, Vallet T, Nugier F, Grange J, Malley S, Hamedi-Sangsari F, Vila J (1995) Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol 10: 36
3. Blumenreich MS, Kellihan MJ, Joseph UG, Lalley KA, Sherrill EJ, Sullivan DM, Hamm JT, Gentile PS, Sheth SP, Seeger J, Woodcock TM (1993) Long-term intravenous hydroxyurea infusions in patients with advanced cancer: a phase I study. Cancer 71: 2828
4. Christen RD, Shalinsky DR, Howell SB (1992) Enhancement of the loss of multiple drug resistance by hydroxyurea. Semin Oncol 19 [Suppl 9]: 94
5. Eckhardt SG, Dai A, Davidson KK, Forseth BJ, Wahl GM, Von Hoff DD (1994) Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc. Proc Natl Acad Sci USA 91: 6674
6. Fabricius E, Rajewsky MF (1971) Determination of hydroxyurea in mammalian tissues and blood. Rev Eur Etudes Clin Biol 16: 679
7. Gao WY, Johns DG, Chokekuchai S, Mitsuya H (1995) Disparate actions of hydroxyurea in potentiation of purine and pyrimidine 2′,3′-dideoxynucleoside activities against replication of human immunodeficiency virus. Proc Natl Acad Sci USA 92: 8333
8. Howell SB, Streifel JA, Pfeifle CE (1982) Modulation of the cellular pharmacology and clinical toxicity of 1-beta-D-arabinofur-anosylcytosine. Med Pediatr Oncol 10 [Suppl 1]: 81
9. Malley SD, Grange JM, Hamedi-Sangsari F, Vila JR (1994) Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2′,3′-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci USA 91: 11017
10. Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F (1986) Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukemia. Tumori 72: 317
11. Moore EC, Hurlbert RB (1989) The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). In: Cory JG, Cory AH (eds) Inhibitors of ribonucleoside diphosphate reductase activity. Pergamon Press, New York, p 165
12. Moran RG, Danenberg PV, Heidelberger C (1982) Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesis. Biochem Pharmacol 31: 2929
13. Muggia FM, Moran RG (1992) Treatment of colon cancer based on biochemical modulation of fluoropyrimidines by hydroxyurea. Semin Oncol 19 [Suppl 9]: 90
14. Raschko JW, Akman SA, Leong LA, Margolin KA, Morgan RJ, Newman E, Somlo G, Ahn C, Doroshow JH (1994) Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. Cancer Chemother Pharmacol 35: 161
15. Rauscher F, Cadman E (1983) Biochemical and cytokinetic modulation of L1210 and HL-60 cells by hydroxyurea and effect on 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity. Cancer Res 43: 2688
16. Smith DC, Vaughan WP, Gwilt PR, Trump DL (1993) A phase I trial of high-dose continuous-infusion hydroxyurea. Cancer Chemother Pharmacol 33: 139
17. Snapka RM, Varshavsky A (1983) Loss of unstably amplified dihydrofolate reductase genes from mouse cells is greatly accelerated by hydroxyurea. Proc Natl Acad Sci USA 80: 7533
18. Tracewell WG, Trump DL, Vaughan WP, Smith DC, Gwilt PR (1995) Population pharmacokinetics of hydroxyurea in cancer patients. Cancer Chemother Pharmacol 35: 417
19. Von Hoff DD, Waddelow T, Forseth B, Davidson K, Scott J, Wahl G (1991) Hydroxyurea accelerates loss of extrachromosomally amplified genes from tumor cells. Cancer Res 51: 6273
20. Yarbro JW (1992) Mechanism of action of hydroxyurea. Semin Oncol 19 [Suppl 9]: 1